User:Mr. Ibrahem/Epcoritamab

Epcoritamab, sold under the brand name Epkinly, is a medication used to treat diffuse large B-cell lymphoma (DLBCL). It is used when other treatments are not effective. It is given by injection under the skin.

Common side effects include cytokine release syndrome, tiredness, musculoskeletal pain, injection site reactions, fever, abdominal pain, nausea, and diarrhea. Other side effects may include infection and low blood cells. Use in pregnancy may harm the baby. It is a monoclonal antibody that is a bispecific CD20-directed CD3 T-cell engager.

Epcoritamab was approved for medical use in the United States in 2023. In the United States it costs about 18,000 USD per dose as of 2023.